DAVION HEALTHCARE PLC (DAVI) Form 6-K — Oct 27, 2026
Davion Healthcare announced the completed acquisition of intellectual property for WoundSkan, a battery-free smartphone-read wound-temperature dressing, and the Spektra Lateral Flow Test, a two-minute multi-marker screening platform, from the four shareholders of Humaskan Ltd. The total consideration is US$25 million: US$2.5 million in cash (payable within 120 days of Nasdaq trading commencing, by 19 February 2027) plus 1,730,770 new shares at a fixed contractual value of US$13.00 per share (~US$22.5 million), issued after a 90-day deferral period. Following issuance, sellers face a 90-day leak-out limiting sales to 10% of Davion's five-day average daily volume per day.
Key figures
- Deal Value Usd
- 25000000
- Shares Offered
- 1730770
- Leakout days
- 90
- Leakout daily limit
- 10% of 5-day average daily volume
- Cash consideration usd
- 2500000
- Deferred issuance days
- 90
- Share consideration usd
- 22500000
- Cash payment deadline days
- 120
- Contractual share value usd
- 13
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.